Literature DB >> 2565516

Association between biological properties of human immunodeficiency virus variants and risk for AIDS and AIDS mortality.

M Tersmette1, J M Lange, R E de Goede, F de Wolf, J K Eeftink-Schattenkerk, P T Schellekens, R A Coutinho, J G Huisman, J Goudsmit, F Miedema.   

Abstract

49 individuals seropositive for human immunodeficiency virus (HIV) antibody were studied longitudinally for the relation between in-vitro properties of their sequential HIV isolates and clinical course before and after the development of AIDS. They were classified into three groups according to the syncytium-inducing capacity, replication rate, and host range of their HIV isolates. The most rapid progression to AIDS (median 15 months) and the lowest survival rate following AIDS diagnosis (median survival 12.5 months) were observed in individuals with high-replicating, syncytium-inducing HIV isolates, followed by individuals with high-replicating, non-syncytium-inducing isolates. In contrast, most individuals with low-replicating, non-syncytium-inducing HIV isolates remained symptom-free during the study period (median follow-up until AIDS diagnosis greater than 42 months), and the few individuals from this group in whom AIDS developed were still alive at the end of the study period (median survival greater than 34 months). In addition, AIDS patients from the three groups differed with respect to their symptoms. Zidovudine treatment in the symptom-free period seemed to delay the onset of AIDS in all risk groups, although stabilisation of CD4+ cell numbers was observed only in individuals with non-syncytium-inducing HIV variants.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2565516     DOI: 10.1016/s0140-6736(89)92628-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  118 in total

1.  Preferential coreceptor utilization and cytopathicity by dual-tropic HIV-1 in human lymphoid tissue ex vivo.

Authors:  S Glushakova; Y Yi; J C Grivel; A Singh; D Schols; E De Clercq; R G Collman; L Margolis
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

2.  Human immunodeficiency virus type 1 induces apoptosis in CD4(+) but not in CD8(+) T cells in ex vivo-infected human lymphoid tissue.

Authors:  J C Grivel; N Malkevitch; L Margolis
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

3.  Membrane-fusing capacity of the human immunodeficiency virus envelope proteins determines the efficiency of CD+ T-cell depletion in macaques infected by a simian-human immunodeficiency virus.

Authors:  B Etemad-Moghadam; D Rhone; T Steenbeke; Y Sun; J Manola; R Gelman; J W Fanton; P Racz; K Tenner-Racz; M K Axthelm; N L Letvin; J Sodroski
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

4.  Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution.

Authors:  J J De Jong; A De Ronde; W Keulen; M Tersmette; J Goudsmit
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

5.  Intrinsic obstacles to human immunodeficiency virus type 1 coreceptor switching.

Authors:  Cristina Pastore; Alejandra Ramos; Donald E Mosier
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

6.  Characterization of a thymus-tropic HIV-1 isolate from a rapid progressor: role of the envelope.

Authors:  Eric G Meissner; Karen M Duus; Feng Gao; Xiao-Fang Yu; Lishan Su
Journal:  Virology       Date:  2004-10-10       Impact factor: 3.616

Review 7.  Drug discovery research targeting the CXC chemokine receptor 4 (CXCR4).

Authors:  Won-Tak Choi; Srinivas Duggineni; Yan Xu; Ziwei Huang; Jing An
Journal:  J Med Chem       Date:  2011-12-02       Impact factor: 7.446

8.  Both the V2 and V3 regions of the human immunodeficiency virus type 1 surface glycoprotein functionally interact with other envelope regions in syncytium formation.

Authors:  A C Andeweg; P Leeflang; A D Osterhaus; M L Bosch
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

9.  Increased neutralization sensitivity of recently emerged CXCR4-using human immunodeficiency virus type 1 strains compared to coexisting CCR5-using variants from the same patient.

Authors:  Evelien M Bunnik; Esther D Quakkelaar; Ad C van Nuenen; Brigitte Boeser-Nunnink; Hanneke Schuitemaker
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

10.  In vivo distribution and cytopathology of variants of human immunodeficiency virus type 1 showing restricted sequence variability in the V3 loop.

Authors:  Y K Donaldson; J E Bell; E C Holmes; E S Hughes; H K Brown; P Simmonds
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.